ORION OYJ

Their core work

Orion is a major Finnish pharmaceutical company focused on developing prescription drugs, particularly in neuroscience and oncology. Within H2020, they contribute pharmaceutical industry expertise to large public-private research initiatives, providing clinical development knowledge, drug safety data, and access to proprietary compounds. Their participation spans from preclinical safety science and systems pharmacology to clinical-stage programs like the CDNF protein therapy for Parkinson's disease, reflecting a company that actively invests in translational medicine through collaborative research.

What they specialise in

How they've shifted over time

Orion's early H2020 involvement (2016–2017) concentrated on classical neuroscience drug discovery — Alzheimer's neuroinflammation targets (TREM2, CD33), Parkinson's disease therapeutics (CDNF protein), and foundational drug safety modelling (systems pharmacology, PBPK). Their later projects (2018–2019) shifted toward digital and data-driven approaches: digital endpoints for measuring fatigue and daily activity, big data analytics for prostate cancer, and preclinical data quality standards. This trajectory mirrors the broader pharmaceutical industry's move from molecule-centric R&D toward patient-centric, digitally-enabled clinical development.

Orion is moving from traditional CNS drug development toward integrating digital biomarkers and real-world evidence into clinical programmes, making them a strong partner for projects bridging pharma with digital health.

How they like to work

Orion participates exclusively as a consortium partner, never as coordinator — consistent with large pharma's typical role in IMI and RIA projects, contributing industry assets (compounds, data, clinical infrastructure) rather than leading academic-style project management. With 143 unique partners across 19 countries from just 6 projects, they operate in very large, multi-stakeholder consortia typical of Innovative Medicines Initiative collaborations. This signals a company comfortable in complex, multi-party environments and willing to share pre-competitive data.

Orion has built an extensive network of 143 unique partners across 19 countries through just 6 large-scale consortia, reflecting deep integration into Europe's public-private pharmaceutical research ecosystem. Their reach spans across most of the EU, with particularly strong ties to academic medical centres and other pharma companies typical of IMI-style projects.

What sets them apart

Orion brings the perspective of a mid-size, independent European pharmaceutical company — large enough to contribute meaningful clinical and preclinical assets, yet more agile and accessible than the top-10 pharma giants that dominate IMI consortia. Their dual strength in neuroscience therapeutics and emerging digital health capabilities positions them at the intersection of traditional drug development and modern clinical measurement. For consortium builders, they offer a pharma industry partner with genuine CNS pipeline expertise and a track record of sustained engagement in collaborative research.

Highlights from their portfolio

• TreatER
  The only project where Orion received direct EC funding — a clinical study of CDNF protein therapy for Parkinson's disease, suggesting Orion's direct involvement in a first-in-human therapeutic approach.
• IDEA-FAST
  A large-scale initiative running until 2026 to develop digital endpoints for neurodegenerative and inflammatory diseases — represents Orion's strategic move into digital biomarkers.
• PHAGO
  Targets TREM2 and CD33 pathways in Alzheimer's neuroinflammation — high-profile drug targets that have attracted significant industry investment globally.